Risk-reducing salpingo-oophorectomy: A meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers

Claudia Marchetti*, Felice F. De, I. Palaia, G. Perniola, A. Musella, D. Musio, L. Muzii, V. Tombolini, P. B. Panici

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: Women with BRCA1 and BRCA2 mutation carriers are at substantially elevated risk of developing ovarian cancer. The aim of the meta-analysis is to clarify the role of risk-reducing salpingo-oophorectomy (RRSO) to reduce ovarian cancer risk and mortality in women with BRCA 1 and BRCA 2 mutation carriers. Methods: Pubmed, Medline and Scopus were searched to select English-language articles. Two investigators independently extracted characteristics and results of selected studies. Articles were included only if prospective and if absolute numbers of ovarian cancer and death events were available or derivable from the test. Pooled hazard ratio (HR) with 95% confidence interval (CI) was calculated using fixed effects model. Results: Meta-analysis of 3 prospective studies demonstrated a significant risk reduction of ovarian cancer with RRSO in BRCA 1 and BRCA 2 mutation carriers, as well as benefit in all-causes mortality incidence. Conclusions: It may be justified to recommend RRSO to reduce ovarian cancer risk and all-causes mortality in women with a mutation in BRCA 1 and BRCA 2.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaBMC Women's Health
Volume14
Numero di pubblicazione1
DOI
Stato di pubblicazionePubblicato - 2014

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2743???
  • ???subjectarea.asjc.2700.2729???

Keywords

  • BRCA
  • Cause
  • Meta-analysis
  • Ovarian cancer
  • Prophylactic
  • Risk-reducing salpingo-oophorectomy

Fingerprint

Entra nei temi di ricerca di 'Risk-reducing salpingo-oophorectomy: A meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers'. Insieme formano una fingerprint unica.

Cita questo